At the time of writing, Enanta Pharmaceuticals Inc [ENTA] stock is trading at $10.86, up 2.16%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ENTA shares have gain 1.78% over the last week, with a monthly amount glided 2.36%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Enanta Pharmaceuticals Inc [NASDAQ: ENTA] stock has seen the most recent analyst activity on October 01, 2025, when Jefferies upgraded its rating to a Buy but kept the price target unchanged to $20 for it. On August 09, 2023, downgrade downgraded it’s rating to Underweight but maintained its price target of $14 on the stock. Jefferies downgraded its rating to a Hold and decreased its price target to $18 on August 08, 2023. H.C. Wainwright initiated its recommendation with a Buy and recommended $56 as its price target on December 09, 2022. Evercore ISI upgraded its rating to Outperform for this stock on July 06, 2022, but kept the price target unchanged to $62. In a note dated June 01, 2022, Evercore ISI upgraded an In-line rating on this stock but restated the target price of $39.
For the past year, the stock price of Enanta Pharmaceuticals Inc fluctuated between $4.09 and $15.34. Currently, Wall Street analysts expect the stock to reach $22 within the next 12 months. Enanta Pharmaceuticals Inc [NASDAQ: ENTA] shares were valued at $10.86 at the most recent close of the market. An investor can expect a potential return of 102.58% based on the average ENTA price forecast.
Analyzing the ENTA fundamentals
According to Enanta Pharmaceuticals Inc [NASDAQ:ENTA], the company’s sales were 64.81M for trailing twelve months, which represents an 1.91% jump. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -1.49%, Pretax Profit Margin comes in at -1.45%, and Net Profit Margin reading is -1.42%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.89 and Total Capital is -0.38. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.61.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.46 points at the first support level, and at 10.05 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.36, and for the 2nd resistance point, it is at 11.85.
Ratios To Look Out For
It is important to note that Enanta Pharmaceuticals Inc [NASDAQ:ENTA] has a current ratio of 5.00. Further, the Quick Ratio stands at 5.00, while the Cash Ratio is 1.01. Considering the valuation of this stock, the price to sales ratio is 4.83, the price to book ratio is 2.93.
Transactions by insiders
Recent insider trading involved Luly Jay R., President and CEO, that happened on Feb 12 ’25 when 45000.0 shares were purchased. Chief Product Strategy Officer, Kieffer Tara Lynn completed a deal on Dec 06 ’24 to sell 2283.0 shares. Meanwhile, Chief Business Officer Luu Brendan sold 2283.0 shares on Dec 06 ’24.
